MedImmune synergy for immuno-oncology clinical trial Advaxis.

Advaxis, MedImmune synergy for immuno-oncology clinical trial Advaxis, Inc Læs mere . , a clinical-stage biotechnology company developing cancer immunotherapies, offers entered into a medical trial collaboration with MedImmune, the global biologics study and development arm of AstraZeneca. Preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as for example MEDI4736, can enhance overall anti-tumour response. Bahija Jallal, Executive Vice President, MedImmune.